智通财经记者 | 范易成 智通财经编辑 | 庄键 一组组数据背后，一场新旧经济动能转换正在悄然发生，上海以其特有的方式展现着一座超大型城市的 韧性。 上海市统计局数据1月21日发布的数据显示，2025年上海GDP升至56708.71亿元，同比增长5.4%，高于 5%的全国GDP增速。 回看过往三年的数据：2023年上海GDP同比增长5.0%，低于全国的5.2%。2024年同比增长5.0%，与全 国持平。2025年上海经济又一次开始领跑，用三年时间画出了一条经济"反弹曲线"。 在2023年5月举行的上海市委常委会会议上，市委书记陈吉宁强调，要抓牢实体经济这个根本，坚定推 动经济转型升级，加快提升产业能级和核心竞争力。 在上海发展改革研究院副院长马海倩看来，上海经济转型升级的关键在于新质生产力驱动的工业体系升 级。她观察到，过去三年间，以集成电路、生物医药、人工智能三大先导产业为代表的先进制造已逐渐 成势。 2024年上海三大先导工业产值同比增长10.8%，2025年总产值进一步实现9.6%的增幅。马海倩对智通财 经表示，上海的这一结构性优势并非一蹴而就，而是源于多年来对三大先导产业的持续深耕与全链条布 局。 以 ...

Core Insights - 2025 is a landmark year for Chinese innovative drugs going global, with total BD (business development) outbound licensing transaction value reaching $135.655 billion and transaction count hitting 157, both setting historical highs [1] - The continuous execution of BD transactions in 2026 validates the global competitiveness of Chinese innovative drugs, with innovation remaining the main investment theme in the pharmaceutical industry [1] Group 1: Market Trends - The small nucleic acid drug sector is attracting more attention from leading companies due to advancements in new target development and treatment convenience, alongside continuously validated clinical data, accelerating outbound licensing and merger collaborations [1] - In the GLP-1 sector, a new pricing system is forming in the domestic market, but the long-term market potential remains promising due to the large patient population for weight loss and diabetes [1] - The development of oral autoimmune drugs is gaining focus, with domestic companies exploring related new targets [1] Group 2: Investment Products - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, selecting listed companies focused on new drug research and development in the biotech and chemical pharmaceutical sectors to reflect the overall trend and market performance of China's pharmaceutical industry innovation [1]

Core Insights - The release of the "Suggestions for Formulating the 15th Five-Year Plan for National Economic and Social Development of Shanghai" marks the beginning of a new development phase for Shanghai, with a focus on enhancing technological innovation capabilities [1] - The establishment of the Pudong Capital Investment and Operation Co., Ltd. with a registered capital of 10 billion yuan serves as a specialized platform for state-owned capital operation, aligning with the plan's emphasis on resource integration and industrial empowerment [1][2] Opportunities and Challenges - **Opportunities**: The plan identifies three core opportunities for Pudong, including the elevation of innovation capabilities, empowerment of industrial ecosystems, and breakthroughs in institutional innovation [2][3] - **Challenges**: Pudong faces internal structural shortcomings and external competitive pressures, necessitating effective responses through the operationalization of Pudong Capital [4][5] Action Requirements - The plan outlines three rigid requirements for Pudong's innovation efforts: strengthening the core engine of the international technology innovation center, achieving decisive progress in key industries, and optimizing the innovation ecosystem [5][6] Next Steps for Pudong's Innovation Work - **Platform Support**: Enhance the innovation platform system to support Shanghai's technological innovation, focusing on integrating research and testing capabilities [8] - **Industry Focus**: Concentrate on overcoming challenges in key industries such as integrated circuits and high-end pharmaceuticals, while fostering new growth areas like quantum technology [9] - **Institutional Innovation**: Implement regulatory innovations to reduce transaction costs for innovation enterprises and enhance the overall innovation service efficiency [10] - **Collaboration Enhancement**: Strengthen internal and external collaborative innovation networks to integrate Shanghai's innovation resources into a global framework [12]

Core Viewpoint - Bidafarma has invested in Hanshi Aitai, becoming one of its significant shareholders, and is inquiring about the innovative directions and achievements of Hanshi Aitai, as well as potential collaborations in technology and sales [1] Group 1: Company Overview - Hanshi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. is an innovative biotech company focused on structural biology, translational medicine, and clinical development [1] - The company has established a product pipeline centered on self-innovated drugs targeting tumors and immune diseases [1] Group 2: Technological Innovations - Hanshi Aitai has developed a globally patented high-affinity, long half-life antibody screening platform [1] - The company has also created an innovative technology platform for tumor-targeted Geographical Positioning Small molecule-Antibody (GPSmAb) [1] Group 3: Shareholding and Future Collaborations - Bidafarma currently holds a 4.72% stake in Hanshi Aitai [1] - Any significant future collaborations will be disclosed in accordance with legal regulations [1]

Core Insights - The economic performance of Shanghai in 2025 shows a year-on-year industrial value-added growth of 5.0% and a total industrial output value growth of 4.6% [2][5] - Strategic emerging industries in Shanghai are projected to grow by 6.5%, increasing their share of the total industrial output value to 45% in 2025, up from 43.6% in 2024 [2][5] - The three leading industries in Shanghai are expected to see a manufacturing output growth of 9.6%, with integrated circuit manufacturing growing by 15.1% and artificial intelligence manufacturing by 13.6% [2][5] Industrial Growth - The total output value of Shanghai's strategic emerging industries is expected to grow by 6.5% in 2025, with the new energy industry growing by 12.9% and high-end equipment industry by 11.1% [2][5] - The "14th Five-Year Plan" emphasizes that this period is crucial for Shanghai's comprehensive development and transformation [2][5] Policy Initiatives - The "14th Five-Year Plan" suggests accelerating the development of three leading industries, enhancing the capabilities and manufacturing levels of integrated circuit equipment, and promoting breakthroughs across the entire industrial chain [4][7] - The plan also focuses on advancing artificial intelligence innovations and improving the development of high-performance computing chips and intelligent technology [4][7] - Shanghai's traditional manufacturing sector will concentrate on product value enhancement, efficiency improvement, and structural optimization to transition from a following position to a leading one [4][7]

Core Insights - The equity investment industry is entering a "refinement period" characterized by a return to cognition and capability reshaping, with long-term capital expanding and patient capital becoming a core force supporting technological innovation [3][41] - Investment institutions are focusing on hard technology and strategic emerging industries, deepening their layouts and uncovering value [3][41] - The conference aims to create an efficient ecosystem that integrates investors and enterprises, promoting the full-chain integration of the investment industry [3][41] Group 1: Institutional Positioning and Core Advantages - The forum features prominent figures from leading investment institutions, emphasizing their long-term commitment and sensitivity to cyclical and structural changes [5][42] - 弘毅投资 has shifted its focus to early-stage technology investments, aligning with national policies and industry trends, while also managing a significant real estate investment business [7][8] - 华映资本 has a strong emphasis on early-stage investments, with over 80% of its investments concentrated in this phase, particularly in AI and related fields [10][11] Group 2: Investment Strategies and Opportunities - Investment strategies for 2026 will focus on AI, biomedicine, and gene technology, with a recognition of the need for a forward-looking perspective on how AI will reshape industries [19][20] - The importance of early-stage investments is highlighted, with institutions planning to deepen their engagement in sectors like semiconductors and artificial intelligence [15][22] - 鼎晖投资 emphasizes a dual structure of traditional PE and VGC, focusing on both acquisition investments and innovative growth funds in hard technology sectors [13][14] Group 3: Balancing Policy Guidance and Investment Returns - The concept of "patient capital" is discussed, with a distinction between "active patience" and "passive patience," emphasizing the need for a proactive approach to long-term investments [32][36] - The balance between policy direction and market logic is crucial, with a focus on finding projects that align with both government strategies and market demands [33][34] - The need for a diversified capital structure to support long-term investments in hard technology is emphasized, highlighting the role of various capital sources [32][33]

Group 1 - The core viewpoint emphasizes that future investments in the pharmaceutical sector should focus on the intrinsic logic of clinical value [1] - The pharmaceutical and biotechnology sectors are driven by innovation (overseas expansion, AI, new technologies), performance validation, policy dividends, and the spring market effect, with a short-term focus on innovative drugs and CXO [1] - High elasticity sub-themes include AI healthcare/AI pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs, while the innovative drug industry chain and innovative medical devices are viewed positively [1] Group 2 - In the innovative medical device sector, there is optimism regarding the upgrade of high-end medical devices and high-value consumables [1] - With the global return to a rate-cutting cycle and structural policy shifts domestically, medical insurance negotiations support innovative drugs, and centralized procurement stabilizes industry profitability [1] - The valuation of the pharmaceutical sector is expected to steadily recover from the first quarter of 2025, with a clear trend of industrial quality improvement and enhanced international competitiveness [1] Group 3 - The Guotai ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on the innovative biopharmaceutical field, selecting listed companies involved in biotechnology, pharmaceuticals, and related medical services to reflect the overall performance of innovative biopharmaceutical securities [1]

Policy Developments - The National Healthcare Security Administration has issued a guideline for the pricing of surgical and treatment auxiliary operations, focusing on medical technology innovations such as robotic surgery and 3D printing, establishing 37 pricing items and guiding the transition from traditional to precision medicine [2] Drug and Device Approvals - Bailitianheng's drug application for iza-bren, a first-in-class EGFR×HER3 dual antibody ADC for treating recurrent or metastatic esophageal squamous cell carcinoma, has been accepted and prioritized for review by the National Medical Products Administration [4] - Heng Rui Medicine has received clinical trial approval for SHR-9839, a humanized antibody for advanced solid tumors, and HRS-4642, a KRAS G12D inhibitor [5] - Fosun Pharma's subsidiary has been approved to conduct clinical trials for HLX701 in combination with chemotherapy for advanced colorectal cancer [6] Capital Market Activities - InnoCare Pharma has entered a collaboration agreement with Shenzhen Hengtai Biotechnology for the ISM8969 project, a new NLRP3 inhibitor for CNS diseases, with a potential total payment of up to $66 million [8][9] - Zhejiang Dejin Bio completed a multi-million A round financing to advance its core product, a recombinant botulinum toxin, and for international expansion [10] Industry Developments - Ant Group's Antifor has launched a DeepSearch feature on its PC platform to assist medical professionals with literature searches and clinical diagnosis [12] - Guangzhou's political advisor has proposed a plan to develop the brain-computer interface industry, aligning with national strategies and leveraging local resources [13] Shareholder Actions - Meihua Medical announced that shareholders plan to reduce their holdings by up to 2.51% of total shares due to personal financial needs [15] - Kain Technology has voluntarily withdrawn its drug registration application for a new hepatitis B indication, which will impact its 2025 profits [16]

Core Viewpoint - The recent delisting of SPACs associated with Chinese companies has halted their plans for U.S. listings, highlighting the risks of the SPAC model and the unique value of the OTC market [1] Group 1: SPAC Delisting and Its Implications - Nasdaq delisted 13 securities on January 13, including three SPACs (Four Leaf, DT Cloud, AlphaTime) linked to Chinese companies, transferring them to the OTC market [1] - The delisting exposes the vulnerabilities of the SPAC model, particularly the reliance on the SPAC's continued listing status [4] - The case of Xiaoyu Tidata illustrates that even with stable business operations, a SPAC's delisting can abruptly halt the entire listing process [4] Group 2: Regulatory Changes and Challenges - New Nasdaq regulations effective January 17, 2026, will raise the minimum public float market value requirement from $5 million to $15 million and mandate that SPAC mergers must raise at least $25 million in public funds [4] - These regulatory changes create significant barriers for many small and medium-sized enterprises [4] Group 3: Advantages of the OTC Market - The OTC market offers a crucial buffer, allowing SPACs to continue merger transactions even after delisting from the main board [5] - OTC has lower financial requirements, with no strict profitability criteria and minimal annual fees ranging from a few thousand to $20,000 [6] - The listing process on the OTC market can be completed in 3-6 months, significantly faster than the 12-24 months required for a Nasdaq IPO [7] Group 4: Structured Compliance and Growth Opportunities - The OTC market features a four-tier compliance structure, catering to different stages of company development [8] - Companies already listed on domestic boards can issue ADRs on OTCQX without meeting stringent SEC registration requirements, facilitating exposure to U.S. investors [9] - The OTC market serves as a "golden stepping stone" for companies aiming to transition to Nasdaq or NYSE, with approximately 15% of Nasdaq-listed companies having previously grown on the OTC market [10] Group 5: Diverse Financing Options - The OTC market supports various financing methods, including private placements and convertible bonds, which are particularly suitable for light-asset companies in technology and biomedicine [11] - Companies can leverage the OTC market to access global financing while providing liquidity options for early investors [11] - The current delisting trend reinforces the need for Chinese companies to consider paths beyond the main board for U.S. listings [11]

Core Viewpoint - The economic performance of Shanghai in 2025 shows a positive trend in emerging industries, with a GDP growth of 5.4% and significant increases in industrial output and investment [3][4]. Economic Performance - In 2025, Shanghai's GDP reached 56,708.71 billion yuan, reflecting a year-on-year growth of 5.4% at constant prices [3]. - The industrial added value in Shanghai grew by 5.0%, with the total industrial output value increasing by 4.6% [3]. - Key sectors such as railway, shipbuilding, aerospace, and other transportation equipment manufacturing saw a remarkable growth of 15.8% [3]. Investment Trends - Fixed asset investment in Shanghai's industrial sector rose by 20.0%, significantly outpacing the overall fixed asset investment growth rate by 15.4 percentage points [3]. - The three leading industries in Shanghai's manufacturing sector achieved a year-on-year output growth of 9.6%, surpassing 2 trillion yuan in total scale [4]. Emerging Industries - The integrated circuit manufacturing sector experienced a growth of 15.1%, while artificial intelligence manufacturing grew by 13.6% in 2025 [4]. - Strategic emerging industries in Shanghai saw a 6.5% increase in output, with the new energy sector growing by 12.9% and high-end equipment manufacturing by 11.1% [4]. Industrial Strategy - Shanghai aims to enhance its industrial structure by focusing on advanced manufacturing, with a modern industrial system framework of "2+3+6+6" [5]. - The three leading industries identified are integrated circuits, biomedicine, and artificial intelligence, which are expected to drive industrial development during the 14th Five-Year Plan period [5]. AI Industry Developments - In a recent month, five AI companies in Shanghai went public, indicating a robust growth trajectory in the AI sector [5]. - Shanghai's local AI company, Xiyu Technology, became the fastest AI company globally to reach IPO status, highlighting the rapid development in this field [5]. Integrated Circuit Industry - Shanghai has established a comprehensive integrated circuit industry chain, excelling in chip design, manufacturing, and testing, with 35 listed companies on the Sci-Tech Innovation Board [7]. - The city is a leader in chip design and manufacturing, with advancements in packaging and high-end equipment materials supporting the growth of AI chip enterprises [7].